F-star updates on FS118 Clinical Trial and Announces Presentation at ASCO 2019
F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today provides a Phase 1 clinical update on its wholly-owned lead programme FS118 and announces a presentation at the ASCO Annual Meeting (Chicago, 01 June 2019). The abstract is currently available on the meeting library webpage .
FS118 is a LAG-3/PD-L1-targeting tetravalent bispecific antibody, in a Phase 1 study in patients with late stage solid tumours who have relapsed following prior PD-(L)1 therapy. The objectives of the study are to evaluate the safety and pharmacokinetics of FS118, as well as clinical activity and immunogenicity. Exploratory assessment of pharmacodynamic response markers are also included.
As a supplement to the ASCO presentation, F-star provides an update on the Phase 1 study, showing:
- FS118 weekly treatment is well tolerated at all dose levels tested to date and has reached the planned highest dose level without occurrence of DLT in the treatment of 29 subjects recruited to date
- Modulation of soluble LAG-3 in patients’ serum as a PD marker of target engagement
“We are very encouraged by the FS118 emerging safety profile and by the early pharmacodynamic observations in advanced cancer patients who have relapsed following PD-(L)1 containing treatments” said Neil Brewis, Chief Scientific Officer of F-star. “LAG-3 is an exciting target in clinical immuno-oncology as it is involved in the development of PD-(L)1-resistance in many indications. We believe FS118 is an important part of the exciting next wave of checkpoint therapies and we are looking forward to generating additional data to validate our approach.”
The study is advancing as expected and is currently recruiting in the expansion cohorts of the two highest dose levels. First study data, including six-month data on clinical response, are expected to be released in Q1 2020.
Details of the poster are below:
A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
Category: Developmental Immunotherapy and Tumor Immunobiology
Date and Time: 01 June from 08:00 - 11:00
Poster Session: Board #292a
Location: McCormick Place - Chicago, IL
Abstract Number: TPS2652
The poster will be available on F-star’s website at the end of the conference.
- ENDS -
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
Currently in a Phase 1 trial at four clinical sites in the United States, FS118 is a potentially first-in-class medicine for the treatment of resistant and refractory cancer. This tetravalent, bispecific antibody is developed to overcome tumour evasion mechanisms promoted by two highly immuno-suppressive molecules: LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1). By simultaneously blocking both inhibitory pathways, FS118 has preclinically demonstrated a potent anti-tumour growth activity(1) as well as a highly differentiated mechanism of action(2) when compared to checkpoint monotherapies alone or in combinations.
In April 2018, a Phase 1 clinical study started in patients who have relapsed following a prior
PD-(L)1-containing therapy. Information about the trial is available on clinicaltrials.gov NCT03440437 . FS118 is manufactured at 2000L scale using standard mAb manufacturing processes.
(1) Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T cell activation and modulates the tumour microenvironment to promote anti-tumour immune responses. Kraman et al. (April 2018) - Poster at the annual AACR meeting
For investor enquiries
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
NY-MOODY’S-ANALYTICS25.6.2019 15:02:10 CEST | Pressemeddelelse
Moody’s Analytics CreditLens™ Solution Adopted by Over 100 Firms
NY-DILIGENT25.6.2019 15:02:10 CEST | Pressemeddelelse
Modern Governance 3.0: Modern Governance Extends Beyond the Boardroom to Allow Secure Sharing of Files and Collaboration with Auditors, Regulators and Other Third Parties
CA-TRANSPHORM-INC25.6.2019 15:02:10 CEST | Pressemeddelelse
Transphorm Strengthens 900 V GaN Portfolio with Second FET
BOC-GROUP25.6.2019 14:28:06 CEST | Pressemeddelelse
BOC Group Announces the Release of ADONIS NP 7.1 – Igniting A New Era of User Inclusion, Insights & BPM Experience
CA-MATRIXX-SOFTWARE25.6.2019 14:07:04 CEST | Pressemeddelelse
MATRIXX Software Joins Linux Foundation Networking to Advance Next Generation of Telco Services
CNT25.6.2019 14:02:14 CEST | Pressemeddelelse
CNT expands into Benelux region
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum